Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recogn...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 2; no. 1; pp. 112 - 128
Main Authors Lee, Lucia H, Gu, Xin-Xing, Nahm, Moon H
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 14.02.2014
MDPI
Subjects
Epidemiology
Pneumonia
Review
Streptococcus infections
Streptococcus pneumoniae
Vaccines
epidemiology
vaccine
pneumococcal protein
serotype
Streptococcus pneumoniae
Online AccessGet full text

Cover

More Information
Summary:Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines2010112